Name | Olopatadine |
---|---|
Synonyms |
{(11E)-11-[3-(Dimethylamino)propylidene]-6,11-dihydrodibenzo[b,e]oxepin-2-yl}acetic acid
Dibenz[b,e]oxepin-2-acetic acid, 11-[3-(dimethylamino)propylidene]-6,11-dihydro-, (11E)- MFCD00865645 KW 4679 Olopatatadine |
Description | Olopatadine is an orally active and selective histamine 1 (H1) receptor antagonist and a mast cell stabilizer. Olopatadine prevents immunologically stimulated pro-inflammatory mediator release from human conjunctival mast cells. Olopatadine can be used for researching allergic conjunctivitis[1][2]. |
---|---|
Related Catalog | |
Target |
H1 Receptor |
In Vitro | Olopatadine inhibits anti-IgE antibody-mediated release of TNF-α from human conjunctival mast cells, and significantly decreases the mast cell supernatant-mediated upregulation of ICAM (intercellular adhesion molecule)-1 on human conjunctival epithelial cells in vitro[2]. |
References |
Density | 1.2±0.1 g/cm3 |
---|---|
Boiling Point | 523.0±50.0 °C at 760 mmHg |
Molecular Formula | C21H23NO3 |
Molecular Weight | 337.412 |
Flash Point | 270.1±30.1 °C |
Exact Mass | 337.167786 |
PSA | 49.77000 |
LogP | 3.14 |
Vapour Pressure | 0.0±1.4 mmHg at 25°C |
Index of Refraction | 1.641 |
~89% 113806-05-6 |
Literature: WO2006/10459 A1, ; Page/Page column 14-15 ; |
~45% 113806-05-6 |
Literature: WO2010/89268 A2, ; Page/Page column 13-14 ; |
~99% 113806-05-6 |
Literature: US2007/232814 A1, ; Page/Page column 25; 26 ; |
~% 113806-05-6 |
Literature: WO2010/121877 A2, ; Page/Page column 25-26 ; |
~% 113806-05-6 |
Literature: EP2385045 A1, ; |
Precursor 4 | |
---|---|
DownStream 2 | |